Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for May, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- What is the Stock Market's Achilles Heel?
- 3 Dividend Stocks at Reasonable Prices
- RTI: Are You Doing the Elon Musk Trade?
- Buy These ETFs to Profit from "Sector Rotation"
- Oil & Gas Industry Stock Outlook - May 2013
- Uncharted Territory
- 4 Ways to Short Oil with ETFs
- Options Strategies & the Zacks Rank
- This Week's Growth & Income Stocks
- AWS 5/17: The Fed: The Only Game in Town
- PFP 5/17: The ONLY Investment Story
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/17/2013
| Company Name | Symbol | %Change |
|---|---|---|
| VIASAT INC | VSAT | 19.35% |
| OLD SECOND B | OSBC | 5.76% |
| GAMCO INVEST | GBL | 4.61% |
| CORNING INC | GLW | 4.47% |
| SYNCHRONOSS | SNCR | 4.23% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Watson Pharmaceuticals Inc.'s ( ) second quarter 2012 earnings (excluding special items) of $1.42 per share surpassed the Zacks Consensus Estimate by 4 cents. Earnings increased 40.6% from the year-ago period. Double-digit revenue growth helped boost earnings.
Revenues for the reported quarter increased 25.3% to $1.36 billion, beating the Zacks Consensus Estimate of $1.35 billion. All segments contributed to the quarterly revenue growth.
On a reported basis, Watson Pharma recorded a loss of 49 cents per share compared to earnings of 42 cents per share in the year-ago period. The second quarter 2012 reported results reflect the impact of charges related to the upcoming acquisition of Actavis.
Quarterly Details
The company’s Global Generics segment posted sales of $995 million, up 26%. The upside was driven by new product launches including the generic version of Sanofi’s ( SNY - Analyst Report ) blood-thinner Lovenox and Pfizer’s ( PFE - Analyst Report ) cholesterol drug Lipitor (launched in November 2011).
International product sales for the division came in at $210.7 million, up 77%, driven by the acquisition of Specifar Pharmaceuticals in May 2011 and Ascent Pharmahealth Ltd. in January 2012.
Watson Pharma’s Global Brands revenue came in at $119.3 million, up 6%. Increased contributions from products like Rapaflo, Crinone and new product launches (Generess Fe, Rapaflo and Gelnique) aided the performance of the segment. Androderm sales, however, were lower.
Net revenue for the Distribution segment increased 37% during the quarter to $240.9 million, due to increased third-party product launches and higher base business sales. This segment consists of only third-party product sales.
Guides In-Line
The company expects earnings in the range of $5.65 to $5.85 per share (previous guidance - $5.55 to $5.80 per share). The company maintained its revenue guidance of approximately $5.5 billion. The Zacks Consensus Estimate currently stands at $5.75 per share on revenues of $5.5 billion.
Watson Pharma expects the Global Generic segment to post revenues of about $3.9 - $4.1 billion in 2012. Brand segment revenue is expected in the range of $500 - $525 million. Distribution segment revenue is expected to come in at about $950 million - $1 billion.
Neutral on Watson Pharma
We currently have a Neutral recommendation on Watson Pharma, which carries a Zacks #2 Rank (short-term ‘Buy’ rating). We are positive on the company’s upcoming acquisition of Actavis which should be immediately accretive. The deal is slated to go through in the fourth quarter of 2012.
Read the full Analyst Report on SNY
Read the full Analyst Report on PFE